Professional · Issue 3 · 2026-10-04
Halving Airway Clearance Burden in ETI-Treated Children: Stable Lung Function Over 12 Months
Editorially reviewed research summaries, context, and limitations.
Marcus Svedberg, Christina Krantz, Henrik Imberg
Summary: This prospective multicentre observational study from two Swedish CF centres followed 46 children aged 6–17 years on elexacaftor/tezacaftor/ivacaftor (ETI) who reduced hypertonic saline inhalation and airway clearance techniques (ACTs) from twice to once daily over 12 months. The primary outcome, lung clearance index (LCI), showed a small non-significant improvement, while FEV₁% predicted remained essentially unchanged. Antibiotic use fell by 39%, and respiratory symptoms and airway microbiology were stable.
Why it matters: Airway clearance regimens impose a substantial daily burden on children and families, and the question of whether they can be safely reduced in the ETI era is clinically pressing and practically important. This study provides prospective — rather than retrospective or anecdotal — evidence that halving prescribed ACT and hypertonic saline frequency was not associated with measurable pulmonary deterioration over a 12-month horizon. The accompanying reduction in antibiotic use is notable, though its direction of causality is not straightforward to interpret. If this finding is confirmed in larger, longer, and ideally randomized studies, it could meaningfully reshape treatment guidelines and reduce daily treatment burden for thousands of children with CF.
Expert perspective: The study is prospectively designed and uses LCI — a sensitive measure of ventilation inhomogeneity — as its primary endpoint, which is an appropriate choice given that FEV₁ is often near-normal in well-controlled pediatric CF on ETI. The baseline LCI of 6.6 and FEV₁ of 97% predicted confirm that this is a relatively healthy, well-treated cohort, which is both a strength and a limitation, as ceiling effects may mask early subtle deterioration.
The most significant methodological concern is the absence of a control arm. Without a contemporaneous group continuing twice-daily therapy, it is impossible to determine whether stability reflects the safety of the reduction or simply the natural trajectory of ETI-treated children over 12 months. The sample size of 46 is modest, and the 95% confidence interval for the LCI change spans −0.67 to +0.03, meaning a clinically meaningful worsening cannot be ruled out — the study is underpowered to definitively exclude harm. A 12-month follow-up may not capture slower trajectories of structural lung disease progression that become apparent over years, particularly given that bronchiectasis can accrue insidiously even in the absence of symptomatic exacerbations.
The 39% reduction in antibiotic days is striking, but its interpretation is ambiguous: reduced ACT frequency might genuinely reduce antibiotic need, or clinicians and families may have been less inclined to treat minor symptoms aggressively in the context of an intentional protocol-guided reduction, introducing behavioral or ascertainment bias. The clinical bottom line is appropriately cautious: this is a promising, hypothesis-generating result. It should encourage — but not yet justify — broad clinical adoption of reduced ACT regimens outside of structured protocols. A randomized non-inferiority trial with longer follow-up, larger sample size, and imaging endpoints would be the necessary next step.
Relevance: Cystic Fibrosis
Source: https://pubmed.ncbi.nlm.nih.gov/42632792/
---